harpagoside: glycoside of a cyclopenta[c]pyran from root of S. African plant Harpagophytum procumbens DC; structure in Negwer, 5th ed, #5281, 7th ed #9921; Harpagophytum extract WS 1531 is plant extract containing harpagoside; Antidiabetic Agent [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Harpagophytum | genus | A plant genus of the family PEDALIACEAE. Members contain harpagoside.[MeSH] | Pedaliaceae | The sesame family of the order Lamiales that are mainly herbs and shrubs growing in warm regions.[MeSH] |
| Harpagophytum procumbens | species | Species of Harpagophytum. Common name Devil's Claw is also a common name of some PROBOSCIDEA PLANT species.[MeSH] | Pedaliaceae | The sesame family of the order Lamiales that are mainly herbs and shrubs growing in warm regions.[MeSH] |
| ID Source | ID |
|---|---|
| PubMed CID | 5281542 |
| CHEMBL ID | 516702 |
| CHEBI ID | 5625 |
| SCHEMBL ID | 893387 |
| MeSH ID | M0103253 |
| Synonym |
|---|
| smr001233395 |
| MLS002154086 |
| BRD-K07996107-001-03-3 |
| BRD-K07996107-001-01-7 |
| ACON1_000134 |
| NCGC00179325-01 |
| NCGC00179325-02 |
| PRESTWICK3_000988 |
| ACON0_000056 |
| BPBIO1_001161 |
| AB00513986 |
| harpagoside |
| 19210-12-9 |
| C09783 |
| BSPBIO_001055 |
| MEGXP0_000469 |
| LMPR0102070010 |
| MLS002473324 |
| e-harpagoside |
| CHEMBL516702 |
| chebi:5625 , |
| HMS2098E17 |
| [(1s,4as,5r,7s,7as)-4a,5-dihydroxy-7-methyl-1-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,5,6,7a-tetrahydrocyclopenta[c]pyran-7-yl] (e)-3-phenylprop-2-enoate |
| unii-8kgs1dc5zu |
| einecs 242-881-6 |
| (1s-(1alpha,4aalpha,5alpha,7alpha(e),7aalpha))-1,4a,5,6,7,7a-hexahydro-4a,5-dihydroxy-7-methyl-7-((allyl-1-oxo-3-phenyl)oxy)cyclopenta(c)pyran-1-yl-beta-d-glucopyranoside |
| 8kgs1dc5zu , |
| HMS2231N12 |
| S9171 |
| AKOS015896715 |
| .beta.-d-glucopyranoside, (1s,4as,5r,7s,7as)-1,4a,5,6,7,7a-hexahydro-4a,5-dihydroxy-7-methyl-7-(((2e)-1-oxo-3-phenyl-2-propenyl)oxy)cyclopenta(c)pyran-1-yl |
| harpagoside [who-dd] |
| harpagoside [inci] |
| SCHEMBL893387 |
| KVRQGMOSZKPBNS-FMHLWDFHSA-N |
| AC-34268 |
| Q-100231 |
| mfcd00017415 |
| harpagoside, analytical standard |
| harpagoside, primary pharmaceutical reference standard |
| harpagoside, european pharmacopoeia (ep) reference standard |
| NCGC00179325-04 |
| (1s,4as,5r,7s,7as)-4a,5-dihydroxy-7-methyl-1-((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yloxy)-1,4a,5,6,7,7a-hexahydrocyclopenta[c]pyran-7-yl cinnamate |
| Q25099323 |
| (1s,4as,5r,7s,7as)-4a,5-dihydroxy-7-methyl-1-(((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl)oxy)-1,4a,5,6,7,7a-hexahydrocyclopenta[c]pyran-7-yl cinnamate |
| CCG-269650 |
| H10494 |
| CS-0008931 |
| HY-N0396 |
| A880338 |
| harpaside |
| AS-56071 |
| beta-d-glucopyranoside, (1s,4as,5r,7s,7as)-1,4a,5,6,7,7a-hexahydro-4a,5-dihydroxy-7-methyl-7-(((2e)-1-oxo-3-phenyl-2-propenyl)oxy)cyclopenta(c)pyran-1-yl |
| EN300-7357122 |
| (1s,4as,5r,7s,7as)-4a,5-dihydroxy-7-methyl-1-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,4ah,5h,6h,7h,7ah-cyclopenta[c]pyran-7-yl (2e)-3-phenylprop-2-enoate |
| DTXSID101032528 |
Harpagoside (HAR) is a natural compound isolated from Harpagophytum procumbens (devil's claw) It is reported to have anti-inflammatory effects. However, these effects have not been investigated in the context of bone development.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Harpagoside did not inhibit the IL-1β-induced activation of NF-κB and C/EBPβ transcription factors but suppressed the IL-1β-triggered induction, phosphorylation, and DNA binding activity of c-FOS, one of the main components of AP-1 transcription factors." | ( Harpagoside suppresses IL-6 expression in primary human osteoarthritis chondrocytes. Ansari, MY; Haqqi, TM; Haseeb, A, 2017) | 2.62 |
The method was successfully applied to the pharmacokinetic study of harpagoside and cinnamic acid following oral administration of Radix Scrophulariae extract to rats.
| Excerpt | Reference | Relevance |
|---|---|---|
| " In addition, pharmacokinetic parameters of Harpagophytum extracts were investigated in vivo." | ( Investigations on the pharmacokinetic properties of Harpagophytum extracts and their effects on eicosanoid biosynthesis in vitro and ex vivo. Kaszkin, M; Loew, D; Möllerfeld, J; Puttkammer, S; Schrödter, A, 2001) | 0.31 |
| " Furthermore, in 3 independent studies with different numbers of human male volunteers, a Harpagophytum extract was administered orally and tested in whole blood samples for Cys-LT and thromboxane B2 (TXB2) biosynthesis and for the determination of pharmacokinetic parameters of harpagoside." | ( Investigations on the pharmacokinetic properties of Harpagophytum extracts and their effects on eicosanoid biosynthesis in vitro and ex vivo. Kaszkin, M; Loew, D; Möllerfeld, J; Puttkammer, S; Schrödter, A, 2001) | 0.49 |
| " The method was successfully applied to the pharmacokinetic study of harpagoside and cinnamic acid following oral administration of Radix Scrophulariae extract to rats." | ( Simultaneous determination of harpagoside and cinnamic acid in rat plasma by liquid chromatography electrospray ionization mass spectrometry and its application to pharmacokinetic studies. Ruan, JX; Wang, SJ; Zhang, ZQ; Zhao, YH, 2008) | 0.87 |
| " The purpose of this study was to develop an HPLC-UV method for simultaneous determination of harpagoside and cinnamic acid in rat plasma and investigate pharmacokinetic parameters of harpagoside and cinnamic acid after oral administration of xuanshen extract (760 mg kg(-1))." | ( Simultaneous determination of harpagoside and cinnamic acid in rat plasma by high-performance liquid chromatography: application to a pharmacokinetic study. Jin, X; Li, P; Xiao, L; Yang, K; Zhang, Y, 2007) | 0.85 |
| "To study on the effects of Achyranthes bidentata on Tongsaimai pellets main active ingredients chlorogenic acid, isoliquiritin, harpagoside and glycyrrhizin in rats in vivo pharmacokinetic behaviors, a method for the simultaneous determination of chlorogenic acid, isoliquiritin, harpagoside and liquiritigenin in rat plasma was established by UPLC-MS/MS." | ( [Studies on effects of Achyranthes bidentata on tongsaimai pellets main active ingredients chlorogenic acid, isoliquiritin, harpagoside and glycyrrhizin in vivo pharmacokinetics]. Bi, XL; Cheng, J; Di, LQ; Kang, A; Li, JS; Shan, JJ; Zhao, XL, 2014) | 0.81 |
| " Despite the chemical constituents having been clarifying by our previous studies, both of the metabolism and pharmacokinetic studies of XMGJ are unclear." | ( UPLC-Q-TOF-MS and UPLC-MS/MS methods for metabolism profiles and pharmacokinetics of major compounds in Xuanmai Ganjie Granules. Sui, F; Wang, P; Wu, Y; Yang, H, 2019) | 0.51 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " The studies offering preparations with 50-60 mg harpagoside in the daily dosage are of better quality and provide more reliable evidence on efficacy than a proprietary ethanol extract with half the amount of harpagoside per day." | ( Effectiveness of Harpagophytum extracts and clinical efficacy. Chrubasik, S; Conradt, C; Roufogalis, BD, 2004) | 0.58 |
| Class | Description |
|---|---|
| terpene glycoside | A terpenoid in which one or more hydroxy functions are glycosylated. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 3.5481 | 0.1000 | 22.9075 | 100.0000 | AID485364 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 17.7828 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 89.1251 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| geminin | Homo sapiens (human) | Potency | 0.1158 | 0.0046 | 11.3741 | 33.4983 | AID624297 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID361436 | Neuroprotective activity against Sprague-Dawley rat cortical neurons assessed as glutamate-induced LDH release at 10 uM for 1 hr before glutamate challenge measured after 24 hrs by spectrophotometry | 2002 | Journal of natural products, Nov, Volume: 65, Issue:11 | Four new neuroprotective iridoid glycosides from Scrophularia buergeriana roots. |
| AID1483790 | Effect on osteocalcin level in serum of OVX-induced bone loss ICR mouse model at 10 mg/kg, po for 12 weeks by ELISA (Rvb = 176.9 +/- 4.7 ng/ml) | 2017 | Journal of natural products, 02-24, Volume: 80, Issue:2 | Anti-Osteoporotic Activity of Harpagoside by Upregulation of the BMP2 and Wnt Signaling Pathways in Osteoblasts and Suppression of Differentiation in Osteoclasts. |
| AID1483754 | Activation of Wnt signaling pathway in mouse MC3T3-E1 cells assessed as increase in Runx2 protein expression up to 4 uM after 48 hrs in presence of ascorbic acid and beta-glycerophosphate by Western blot analysis | 2017 | Journal of natural products, 02-24, Volume: 80, Issue:2 | Anti-Osteoporotic Activity of Harpagoside by Upregulation of the BMP2 and Wnt Signaling Pathways in Osteoblasts and Suppression of Differentiation in Osteoclasts. |
| AID1243554 | Inhibition of LPS-induced bone loss in ICR mouse assessed as prevention of loss in trabecular bone in femurs at 10 mg/kg, po after 10 days by micro-CT analysis | 2015 | Journal of natural products, Sep-25, Volume: 78, Issue:9 | Harpagoside Inhibits RANKL-Induced Osteoclastogenesis via Syk-Btk-PLCγ2-Ca(2+) Signaling Pathway and Prevents Inflammation-Mediated Bone Loss. |
| AID1243571 | Inhibition of ovariectomized-induced bone loss in C57BL/6 mouse assessed as CTX-I level in serum at 10 mg/kg, po administered every other day for 28 days by ELISA | 2015 | Journal of natural products, Sep-25, Volume: 78, Issue:9 | Harpagoside Inhibits RANKL-Induced Osteoclastogenesis via Syk-Btk-PLCγ2-Ca(2+) Signaling Pathway and Prevents Inflammation-Mediated Bone Loss. |
| AID1483745 | Downregulation of RANKL protein expression in mouse MC3T3-E1 cells up to 4 uM after 48 hrs in presence of ascorbic acid and beta-glycerophosphate by Western blot analysis | 2017 | Journal of natural products, 02-24, Volume: 80, Issue:2 | Anti-Osteoporotic Activity of Harpagoside by Upregulation of the BMP2 and Wnt Signaling Pathways in Osteoblasts and Suppression of Differentiation in Osteoclasts. |
| AID1483748 | Suppression of OCN mRNA expression in mouse MC3T3-E1 cells up to 4 uM after 48 hrs in presence of ascorbic acid and beta-glycerophosphate by real-time PCR analysis | 2017 | Journal of natural products, 02-24, Volume: 80, Issue:2 | Anti-Osteoporotic Activity of Harpagoside by Upregulation of the BMP2 and Wnt Signaling Pathways in Osteoblasts and Suppression of Differentiation in Osteoclasts. |
| AID1243567 | Inhibition of ovariectomized-induced bone loss in C57BL/6 mouse assessed as restoration of Tb.N in femurs at 10 mg/kg, po administered every other day for 28 days by morphometric analysis | 2015 | Journal of natural products, Sep-25, Volume: 78, Issue:9 | Harpagoside Inhibits RANKL-Induced Osteoclastogenesis via Syk-Btk-PLCγ2-Ca(2+) Signaling Pathway and Prevents Inflammation-Mediated Bone Loss. |
| AID467896 | Antiviral activity against HCV expressing E1E2 glycoprotein with Vpr-deficient HIV vector assessed as inhibition of viral entry in human Huh7 cells at 20 ug/ml after 72 hrs by luciferase reporter gene assay in presence of beta-glucosidase enzyme for 4 hrs | 2009 | Journal of natural products, Dec, Volume: 72, Issue:12 | Lamiridosins, hepatitis C virus entry inhibitors from Lamium album. |
| AID1483799 | Downregulation of beta-catenin phosphorylated protein expression in mouse MC3T3-E1 cells up to 4 uM after 48 hrs in presence of ascorbic acid and beta-glycerophosphate by Western blot analysis | 2017 | Journal of natural products, 02-24, Volume: 80, Issue:2 | Anti-Osteoporotic Activity of Harpagoside by Upregulation of the BMP2 and Wnt Signaling Pathways in Osteoblasts and Suppression of Differentiation in Osteoclasts. |
| AID1483771 | Decrease in OVX-induced increase in body weight in ICR mouse at 2 to 10 mg/kg, po for 12 weeks | 2017 | Journal of natural products, 02-24, Volume: 80, Issue:2 | Anti-Osteoporotic Activity of Harpagoside by Upregulation of the BMP2 and Wnt Signaling Pathways in Osteoblasts and Suppression of Differentiation in Osteoclasts. |
| AID1483747 | Upregulation of ALP protein expression in 2 days differentiated mouse MC3T3-E1 cells up to 4 uM after 48 hrs in presence of ascorbic acid and beta-glycerophosphate by Western blot analysis | 2017 | Journal of natural products, 02-24, Volume: 80, Issue:2 | Anti-Osteoporotic Activity of Harpagoside by Upregulation of the BMP2 and Wnt Signaling Pathways in Osteoblasts and Suppression of Differentiation in Osteoclasts. |
| AID1483780 | Effect on alkaline phosphatase activity in serum of OVX-induced bone loss ICR mouse model at 2 mg/kg, po for 12 weeks using p-NPP as substrate (Rvb = 84.9 +/- 4.2 U/L) | 2017 | Journal of natural products, 02-24, Volume: 80, Issue:2 | Anti-Osteoporotic Activity of Harpagoside by Upregulation of the BMP2 and Wnt Signaling Pathways in Osteoblasts and Suppression of Differentiation in Osteoclasts. |
| AID1243561 | Inhibition of LPS-induced bone loss in ICR mouse assessed as restoration of bone loss in femurs at 10 mg/kg, po after 10 days by hematoxylin and eosin staining | 2015 | Journal of natural products, Sep-25, Volume: 78, Issue:9 | Harpagoside Inhibits RANKL-Induced Osteoclastogenesis via Syk-Btk-PLCγ2-Ca(2+) Signaling Pathway and Prevents Inflammation-Mediated Bone Loss. |
| AID1483742 | Increase in OPG mRNA expression in mouse MC3T3-E1 cells up to 4 uM after 48 hrs in presence of ascorbic acid and beta-glycerophosphate by real-time PCR analysis | 2017 | Journal of natural products, 02-24, Volume: 80, Issue:2 | Anti-Osteoporotic Activity of Harpagoside by Upregulation of the BMP2 and Wnt Signaling Pathways in Osteoblasts and Suppression of Differentiation in Osteoclasts. |
| AID1243544 | Inhibition of RANKL-mediated osteoclastogenesis in mouse BMMC assessed as reduction of beta3-integrin mRNA expression at 100 uM after 12 to 48 hrs by RT-PCR analysis | 2015 | Journal of natural products, Sep-25, Volume: 78, Issue:9 | Harpagoside Inhibits RANKL-Induced Osteoclastogenesis via Syk-Btk-PLCγ2-Ca(2+) Signaling Pathway and Prevents Inflammation-Mediated Bone Loss. |
| AID1243568 | Inhibition of ovariectomized-induced bone loss in C57BL/6 mouse assessed as restoration of osteoclast formation in femurs at 10 mg/kg, po administered every other day for 28 days by hematoxylin and eosin staining | 2015 | Journal of natural products, Sep-25, Volume: 78, Issue:9 | Harpagoside Inhibits RANKL-Induced Osteoclastogenesis via Syk-Btk-PLCγ2-Ca(2+) Signaling Pathway and Prevents Inflammation-Mediated Bone Loss. |
| AID1483752 | Activation of Wnt signaling pathway in mouse MC3T3-E1 cells assessed as increase in BMP2 protein expression up to 4 uM after 48 hrs in presence of ascorbic acid and beta-glycerophosphate by Western blot analysis | 2017 | Journal of natural products, 02-24, Volume: 80, Issue:2 | Anti-Osteoporotic Activity of Harpagoside by Upregulation of the BMP2 and Wnt Signaling Pathways in Osteoblasts and Suppression of Differentiation in Osteoclasts. |
| AID1483792 | Effect on C-terminal telopeptide level in serum of OVX-induced bone loss ICR mouse model at 2 mg/kg, po for 12 weeks by ELISA (Rvb = 95.7 +/- 3.8 ng/ml) | 2017 | Journal of natural products, 02-24, Volume: 80, Issue:2 | Anti-Osteoporotic Activity of Harpagoside by Upregulation of the BMP2 and Wnt Signaling Pathways in Osteoblasts and Suppression of Differentiation in Osteoclasts. |
| AID1243545 | Inhibition of RANKL-mediated osteoclastogenesis in mouse BMMC assessed as reduction of DC-STAMP mRNA expression at 100 uM after 12 to 48 hrs by RT-PCR analysis | 2015 | Journal of natural products, Sep-25, Volume: 78, Issue:9 | Harpagoside Inhibits RANKL-Induced Osteoclastogenesis via Syk-Btk-PLCγ2-Ca(2+) Signaling Pathway and Prevents Inflammation-Mediated Bone Loss. |
| AID1243541 | Inhibition of RANKL-mediated osteoclastogenesis in mouse BMMC assessed as reduction of NFATc1 mRNA expression at 100 uM after 12 to 48 hrs by RT-PCR analysis | 2015 | Journal of natural products, Sep-25, Volume: 78, Issue:9 | Harpagoside Inhibits RANKL-Induced Osteoclastogenesis via Syk-Btk-PLCγ2-Ca(2+) Signaling Pathway and Prevents Inflammation-Mediated Bone Loss. |
| AID1483763 | Inhibition of RANKL/M-CSF-induced osteoclast differentiation in mouse bone marrow-derived osteoclasts assessed as downregulation of c-Fos protein expression up to 4 uM after 48 hrs by Western blot analysis | 2017 | Journal of natural products, 02-24, Volume: 80, Issue:2 | Anti-Osteoporotic Activity of Harpagoside by Upregulation of the BMP2 and Wnt Signaling Pathways in Osteoblasts and Suppression of Differentiation in Osteoclasts. |
| AID1483761 | Inhibition of RANKL/M-CSF-induced osteoclast differentiation in mouse bone marrow-derived osteoclasts assessed as downregulation of TRAP protein expression up to 4 uM after 48 hrs by Western blot analysis | 2017 | Journal of natural products, 02-24, Volume: 80, Issue:2 | Anti-Osteoporotic Activity of Harpagoside by Upregulation of the BMP2 and Wnt Signaling Pathways in Osteoblasts and Suppression of Differentiation in Osteoclasts. |
| AID1483789 | Effect on osteocalcin level in serum of OVX-induced bone loss ICR mouse model at 5 mg/kg, po for 12 weeks by ELISA (Rvb = 176.9 +/- 4.7 ng/ml) | 2017 | Journal of natural products, 02-24, Volume: 80, Issue:2 | Anti-Osteoporotic Activity of Harpagoside by Upregulation of the BMP2 and Wnt Signaling Pathways in Osteoblasts and Suppression of Differentiation in Osteoclasts. |
| AID1483784 | Effect on TRAP activity in serum of OVX-induced bone loss ICR mouse model at 2 mg/kg, po for 12 weeks (Rvb = 19.8 +/- 1.0 U/L) | 2017 | Journal of natural products, 02-24, Volume: 80, Issue:2 | Anti-Osteoporotic Activity of Harpagoside by Upregulation of the BMP2 and Wnt Signaling Pathways in Osteoblasts and Suppression of Differentiation in Osteoclasts. |
| AID1483794 | Effect on C-terminal telopeptide level in serum of OVX-induced bone loss ICR mouse model at 10 mg/kg, po for 12 weeks by ELISA (Rvb = 95.7 +/- 3.8 ng/ml) | 2017 | Journal of natural products, 02-24, Volume: 80, Issue:2 | Anti-Osteoporotic Activity of Harpagoside by Upregulation of the BMP2 and Wnt Signaling Pathways in Osteoblasts and Suppression of Differentiation in Osteoclasts. |
| AID1483774 | Effect on calcium level in serum of OVX-induced bone loss ICR mouse model at 10 mg/kg, po for 12 weeks by ELISA (Rvb = 9.3 +/- 0.3 mg/dl) | 2017 | Journal of natural products, 02-24, Volume: 80, Issue:2 | Anti-Osteoporotic Activity of Harpagoside by Upregulation of the BMP2 and Wnt Signaling Pathways in Osteoblasts and Suppression of Differentiation in Osteoclasts. |
| AID1243559 | Inhibition of LPS-induced bone loss in ICR mouse assessed as reduction of RANKL/OPG ratio in serum level at 10 mg/kg, po after 10 days by ELISA | 2015 | Journal of natural products, Sep-25, Volume: 78, Issue:9 | Harpagoside Inhibits RANKL-Induced Osteoclastogenesis via Syk-Btk-PLCγ2-Ca(2+) Signaling Pathway and Prevents Inflammation-Mediated Bone Loss. |
| AID1483755 | Downregulation of DKK1 protein expression in mouse MC3T3-E1 cells up to 4 uM after 48 hrs in presence of ascorbic acid and beta-glycerophosphate by Western blot analysis | 2017 | Journal of natural products, 02-24, Volume: 80, Issue:2 | Anti-Osteoporotic Activity of Harpagoside by Upregulation of the BMP2 and Wnt Signaling Pathways in Osteoblasts and Suppression of Differentiation in Osteoclasts. |
| AID1483764 | Anti-osteoporotic activity in po dosed OVX-induced bone loss ICR mouse model assessed as decrease in trabecular bone destruction in femur administered for 12 weeks by microcomputed tomography | 2017 | Journal of natural products, 02-24, Volume: 80, Issue:2 | Anti-Osteoporotic Activity of Harpagoside by Upregulation of the BMP2 and Wnt Signaling Pathways in Osteoblasts and Suppression of Differentiation in Osteoclasts. |
| AID1483759 | Cytotoxicity against mouse osteoclasts assessed as effect on cell survival up to 4 uM after 72 hrs by MTT assay | 2017 | Journal of natural products, 02-24, Volume: 80, Issue:2 | Anti-Osteoporotic Activity of Harpagoside by Upregulation of the BMP2 and Wnt Signaling Pathways in Osteoblasts and Suppression of Differentiation in Osteoclasts. |
| AID612347 | Inhibition of ovine COX1 at 2.5 to 100 uM incubated for 10 mins by enzyme immunoassay | 2011 | Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16 | Effects of β-glucosidase hydrolyzed products of harpagide and harpagoside on cyclooxygenase-2 (COX-2) in vitro. |
| AID1243537 | Inhibition of bone resorption in mouse mature osteoclasts after 24 hrs by light microscopic analysis | 2015 | Journal of natural products, Sep-25, Volume: 78, Issue:9 | Harpagoside Inhibits RANKL-Induced Osteoclastogenesis via Syk-Btk-PLCγ2-Ca(2+) Signaling Pathway and Prevents Inflammation-Mediated Bone Loss. |
| AID1243553 | Inhibition of RANKL-mediated osteoclastogenesis in mouse BMMC assessed as reduction of amplitude and frequency of Ca2+ oscillations at 100 uM after 24 hrs by Fura-2/AM fluorescence assay | 2015 | Journal of natural products, Sep-25, Volume: 78, Issue:9 | Harpagoside Inhibits RANKL-Induced Osteoclastogenesis via Syk-Btk-PLCγ2-Ca(2+) Signaling Pathway and Prevents Inflammation-Mediated Bone Loss. |
| AID1483773 | Effect on calcium level in serum of OVX-induced bone loss ICR mouse model at 5 mg/kg, po for 12 weeks by ELISA (Rvb = 9.3 +/- 0.3 mg/dl) | 2017 | Journal of natural products, 02-24, Volume: 80, Issue:2 | Anti-Osteoporotic Activity of Harpagoside by Upregulation of the BMP2 and Wnt Signaling Pathways in Osteoblasts and Suppression of Differentiation in Osteoclasts. |
| AID1483786 | Effect on TRAP activity in serum of OVX-induced bone loss ICR mouse model at 10 mg/kg, po for 12 weeks (Rvb = 19.8 +/- 1.0 U/L) | 2017 | Journal of natural products, 02-24, Volume: 80, Issue:2 | Anti-Osteoporotic Activity of Harpagoside by Upregulation of the BMP2 and Wnt Signaling Pathways in Osteoblasts and Suppression of Differentiation in Osteoclasts. |
| AID1483796 | Increase in OPN mRNA expression in 2 days differentiated mouse MC3T3-E1 cells up to 4 uM after 48 hrs in presence of ascorbic acid and beta-glycerophosphate by real-time PCR analysis | 2017 | Journal of natural products, 02-24, Volume: 80, Issue:2 | Anti-Osteoporotic Activity of Harpagoside by Upregulation of the BMP2 and Wnt Signaling Pathways in Osteoblasts and Suppression of Differentiation in Osteoclasts. |
| AID1483768 | Anti-osteoporotic activity in ovariectomized ICR mouse assessed as increase in trabecular thickness in femur at 2 to 10 mg/kg, po after 12 weeks by microcomputed tomography | 2017 | Journal of natural products, 02-24, Volume: 80, Issue:2 | Anti-Osteoporotic Activity of Harpagoside by Upregulation of the BMP2 and Wnt Signaling Pathways in Osteoblasts and Suppression of Differentiation in Osteoclasts. |
| AID1483782 | Effect on alkaline phosphatase activity in serum of OVX-induced bone loss ICR mouse model at 10 mg/kg, po for 12 weeks using p-NPP as substrate (Rvb = 84.9 +/- 4.2 U/L) | 2017 | Journal of natural products, 02-24, Volume: 80, Issue:2 | Anti-Osteoporotic Activity of Harpagoside by Upregulation of the BMP2 and Wnt Signaling Pathways in Osteoblasts and Suppression of Differentiation in Osteoclasts. |
| AID467899 | Antiviral activity against HCV expressing E1E2 glycoprotein with Vpr-deficient HIV vector assessed as inhibition of viral entry in human Huh7 cells at 20 ug/ml after 72 hrs by luciferase reporter gene assay | 2009 | Journal of natural products, Dec, Volume: 72, Issue:12 | Lamiridosins, hepatitis C virus entry inhibitors from Lamium album. |
| AID1243549 | Inhibition of RANKL-mediated JNK phosphorylation in mouse BMMC at 100 uM after 1 hr by Western blot analysis | 2015 | Journal of natural products, Sep-25, Volume: 78, Issue:9 | Harpagoside Inhibits RANKL-Induced Osteoclastogenesis via Syk-Btk-PLCγ2-Ca(2+) Signaling Pathway and Prevents Inflammation-Mediated Bone Loss. |
| AID1243565 | Inhibition of ovariectomized-induced bone loss in C57BL/6 mouse assessed as restoration of BV/TV in femurs at 10 mg/kg, po administered every other day for 28 days by morphometric analysis | 2015 | Journal of natural products, Sep-25, Volume: 78, Issue:9 | Harpagoside Inhibits RANKL-Induced Osteoclastogenesis via Syk-Btk-PLCγ2-Ca(2+) Signaling Pathway and Prevents Inflammation-Mediated Bone Loss. |
| AID1483776 | Effect on potassium level in serum of OVX-induced bone loss ICR mouse model at 2 mg/kg, po for 12 weeks by ELISA (Rvb = 8.2 +/- 0.4 mg/dl) | 2017 | Journal of natural products, 02-24, Volume: 80, Issue:2 | Anti-Osteoporotic Activity of Harpagoside by Upregulation of the BMP2 and Wnt Signaling Pathways in Osteoblasts and Suppression of Differentiation in Osteoclasts. |
| AID1243534 | Inhibition of RANKL-mediated osteoclast differentiation in mouse BMMC assessed as formation of TRAP-positive osteoclasts after 4 days | 2015 | Journal of natural products, Sep-25, Volume: 78, Issue:9 | Harpagoside Inhibits RANKL-Induced Osteoclastogenesis via Syk-Btk-PLCγ2-Ca(2+) Signaling Pathway and Prevents Inflammation-Mediated Bone Loss. |
| AID1483770 | Anti-osteoporotic activity in ovariectomized ICR mouse assessed as suppression of changes in structure model index levels in femur at 2 to 10 mg/kg, po after 12 weeks by microcomputed tomography | 2017 | Journal of natural products, 02-24, Volume: 80, Issue:2 | Anti-Osteoporotic Activity of Harpagoside by Upregulation of the BMP2 and Wnt Signaling Pathways in Osteoblasts and Suppression of Differentiation in Osteoclasts. |
| AID1243556 | Inhibition of LPS-induced bone loss in ICR mouse assessed as restoration of Tb.Sp in femurs at 10 mg/kg, po after 10 days by morphometric analysis | 2015 | Journal of natural products, Sep-25, Volume: 78, Issue:9 | Harpagoside Inhibits RANKL-Induced Osteoclastogenesis via Syk-Btk-PLCγ2-Ca(2+) Signaling Pathway and Prevents Inflammation-Mediated Bone Loss. |
| AID1243569 | Inhibition of ovariectomized-induced bone loss in C57BL/6 mouse assessed as restoration of bone loss in femurs at 10 mg/kg, po administered every other day for 28 days by hematoxylin and eosin staining | 2015 | Journal of natural products, Sep-25, Volume: 78, Issue:9 | Harpagoside Inhibits RANKL-Induced Osteoclastogenesis via Syk-Btk-PLCγ2-Ca(2+) Signaling Pathway and Prevents Inflammation-Mediated Bone Loss. |
| AID1243557 | Inhibition of LPS-induced bone loss in ICR mouse assessed as restoration of Tb.N in femurs at 10 mg/kg, po after 10 days by morphometric analysis | 2015 | Journal of natural products, Sep-25, Volume: 78, Issue:9 | Harpagoside Inhibits RANKL-Induced Osteoclastogenesis via Syk-Btk-PLCγ2-Ca(2+) Signaling Pathway and Prevents Inflammation-Mediated Bone Loss. |
| AID1483781 | Effect on alkaline phosphatase activity in serum of OVX-induced bone loss ICR mouse model at 5 mg/kg, po for 12 weeks using p-NPP as substrate (Rvb = 84.9 +/- 4.2 U/L) | 2017 | Journal of natural products, 02-24, Volume: 80, Issue:2 | Anti-Osteoporotic Activity of Harpagoside by Upregulation of the BMP2 and Wnt Signaling Pathways in Osteoblasts and Suppression of Differentiation in Osteoclasts. |
| AID1243552 | Inhibition of RANKL-mediated PLCgamma2 phosphorylation in mouse BMMC at 100 uM after 1 hr by Western blot analysis | 2015 | Journal of natural products, Sep-25, Volume: 78, Issue:9 | Harpagoside Inhibits RANKL-Induced Osteoclastogenesis via Syk-Btk-PLCγ2-Ca(2+) Signaling Pathway and Prevents Inflammation-Mediated Bone Loss. |
| AID1483765 | Anti-osteoporotic activity in po dosed OVX-induced bone loss ICR mouse model assessed as increase in bone mineral density administered for 12 weeks by microcomputed tomography | 2017 | Journal of natural products, 02-24, Volume: 80, Issue:2 | Anti-Osteoporotic Activity of Harpagoside by Upregulation of the BMP2 and Wnt Signaling Pathways in Osteoblasts and Suppression of Differentiation in Osteoclasts. |
| AID1483778 | Effect on potassium level in serum of OVX-induced bone loss ICR mouse model at 10 mg/kg, po for 12 weeks by ELISA (Rvb = 8.2 +/- 0.4 mg/dl) | 2017 | Journal of natural products, 02-24, Volume: 80, Issue:2 | Anti-Osteoporotic Activity of Harpagoside by Upregulation of the BMP2 and Wnt Signaling Pathways in Osteoblasts and Suppression of Differentiation in Osteoclasts. |
| AID1483757 | Activation of Wnt signaling pathway in mouse MC3T3-E1 cells assessed as upregulation of cyclin D1 protein expression after 48 hrs in presence of ascorbic acid and beta-glycerophosphate by Western blot analysis | 2017 | Journal of natural products, 02-24, Volume: 80, Issue:2 | Anti-Osteoporotic Activity of Harpagoside by Upregulation of the BMP2 and Wnt Signaling Pathways in Osteoblasts and Suppression of Differentiation in Osteoclasts. |
| AID1483767 | Anti-osteoporotic activity in ovariectomized ICR mouse assessed as increase in trabecular number in femur at 2 to 10 mg/kg, po after 12 weeks by microcomputed tomography | 2017 | Journal of natural products, 02-24, Volume: 80, Issue:2 | Anti-Osteoporotic Activity of Harpagoside by Upregulation of the BMP2 and Wnt Signaling Pathways in Osteoblasts and Suppression of Differentiation in Osteoclasts. |
| AID1483739 | Cytotoxicity against mouse MC3T3-E1 cells assessed as cell viability up to 4 uM after 72 hrs by MTT assay | 2017 | Journal of natural products, 02-24, Volume: 80, Issue:2 | Anti-Osteoporotic Activity of Harpagoside by Upregulation of the BMP2 and Wnt Signaling Pathways in Osteoblasts and Suppression of Differentiation in Osteoclasts. |
| AID1483766 | Anti-osteoporotic activity in ovariectomized ICR mouse assessed as increase in ratio of bone volume to tissue volume of femur at 2 to 10 mg/kg, po after 12 weeks by microcomputed tomography | 2017 | Journal of natural products, 02-24, Volume: 80, Issue:2 | Anti-Osteoporotic Activity of Harpagoside by Upregulation of the BMP2 and Wnt Signaling Pathways in Osteoblasts and Suppression of Differentiation in Osteoclasts. |
| AID1483751 | Activation of Wnt signaling pathway in mouse MC3T3-E1 cells assessed as increase in Runx2 mRNA expression after 48 hrs in presence of ascorbic acid and beta-glycerophosphate by real-time PCR analysis | 2017 | Journal of natural products, 02-24, Volume: 80, Issue:2 | Anti-Osteoporotic Activity of Harpagoside by Upregulation of the BMP2 and Wnt Signaling Pathways in Osteoblasts and Suppression of Differentiation in Osteoclasts. |
| AID361434 | Neuroprotective activity against Sprague-Dawley rat cortical neurons assessed as glutamate-induced LDH release at 0.1 uM for 1 hr before glutamate challenge measured after 24 hrs by spectrophotometry | 2002 | Journal of natural products, Nov, Volume: 65, Issue:11 | Four new neuroprotective iridoid glycosides from Scrophularia buergeriana roots. |
| AID1483762 | Inhibition of RANKL/M-CSF-induced osteoclast differentiation in mouse bone marrow-derived osteoclasts assessed as downregulation of NFATc1 protein expression up to 4 uM after 48 hrs by Western blot analysis | 2017 | Journal of natural products, 02-24, Volume: 80, Issue:2 | Anti-Osteoporotic Activity of Harpagoside by Upregulation of the BMP2 and Wnt Signaling Pathways in Osteoblasts and Suppression of Differentiation in Osteoclasts. |
| AID1243558 | Inhibition of LPS-induced bone loss in ICR mouse assessed as restoration of Tb.Th in femurs at 10 mg/kg, po after 10 days by morphometric analysis | 2015 | Journal of natural products, Sep-25, Volume: 78, Issue:9 | Harpagoside Inhibits RANKL-Induced Osteoclastogenesis via Syk-Btk-PLCγ2-Ca(2+) Signaling Pathway and Prevents Inflammation-Mediated Bone Loss. |
| AID1243542 | Inhibition of RANKL-mediated osteoclastogenesis in mouse BMMC assessed as reduction of TRAP mRNA expression at 100 uM after 12 to 48 hrs by RT-PCR analysis | 2015 | Journal of natural products, Sep-25, Volume: 78, Issue:9 | Harpagoside Inhibits RANKL-Induced Osteoclastogenesis via Syk-Btk-PLCγ2-Ca(2+) Signaling Pathway and Prevents Inflammation-Mediated Bone Loss. |
| AID1483741 | Antiosteoporotic activity in mouse MC3T3-E1 cells assessed as formation of mineralized nodule after 14 days in presence of ascorbic acid and beta-glycerophosphate by Alizarin red S staining-based microscopic method | 2017 | Journal of natural products, 02-24, Volume: 80, Issue:2 | Anti-Osteoporotic Activity of Harpagoside by Upregulation of the BMP2 and Wnt Signaling Pathways in Osteoblasts and Suppression of Differentiation in Osteoclasts. |
| AID1243562 | Inhibition of LPS-induced bone loss in ICR mouse assessed as restoration of number of osteoclasts in femurs at 10 mg/kg, po after 10 days | 2015 | Journal of natural products, Sep-25, Volume: 78, Issue:9 | Harpagoside Inhibits RANKL-Induced Osteoclastogenesis via Syk-Btk-PLCγ2-Ca(2+) Signaling Pathway and Prevents Inflammation-Mediated Bone Loss. |
| AID1243555 | Inhibition of LPS-induced bone loss in ICR mouse assessed as restoration of BV/TV in femurs at 10 mg/kg, po after 10 days by morphometric analysis | 2015 | Journal of natural products, Sep-25, Volume: 78, Issue:9 | Harpagoside Inhibits RANKL-Induced Osteoclastogenesis via Syk-Btk-PLCγ2-Ca(2+) Signaling Pathway and Prevents Inflammation-Mediated Bone Loss. |
| AID1483749 | Upregulation of OCN protein expression in mouse MC3T3-E1 cells up to 4 uM after 48 hrs in presence of ascorbic acid and beta-glycerophosphate by Western blot analysis | 2017 | Journal of natural products, 02-24, Volume: 80, Issue:2 | Anti-Osteoporotic Activity of Harpagoside by Upregulation of the BMP2 and Wnt Signaling Pathways in Osteoblasts and Suppression of Differentiation in Osteoclasts. |
| AID1483753 | Activation of Wnt signaling pathway in mouse MC3T3-E1 cells assessed as increase in Smad protein expression up to 4 uM after 48 hrs in presence of ascorbic acid and beta-glycerophosphate by Western blot analysis | 2017 | Journal of natural products, 02-24, Volume: 80, Issue:2 | Anti-Osteoporotic Activity of Harpagoside by Upregulation of the BMP2 and Wnt Signaling Pathways in Osteoblasts and Suppression of Differentiation in Osteoclasts. |
| AID1483772 | Effect on calcium level in serum of OVX-induced bone loss ICR mouse model at 2 mg/kg, po for 12 weeks by ELISA (Rvb = 9.3 +/- 0.3 mg/dl) | 2017 | Journal of natural products, 02-24, Volume: 80, Issue:2 | Anti-Osteoporotic Activity of Harpagoside by Upregulation of the BMP2 and Wnt Signaling Pathways in Osteoblasts and Suppression of Differentiation in Osteoclasts. |
| AID1243566 | Inhibition of ovariectomized-induced bone loss in C57BL/6 mouse assessed as restoration of Tb.Sp in femurs at 10 mg/kg, po administered every other day for 28 days by morphometric analysis | 2015 | Journal of natural products, Sep-25, Volume: 78, Issue:9 | Harpagoside Inhibits RANKL-Induced Osteoclastogenesis via Syk-Btk-PLCγ2-Ca(2+) Signaling Pathway and Prevents Inflammation-Mediated Bone Loss. |
| AID1483797 | Upregulation of OPN protein expression in 2 days differentiated mouse MC3T3-E1 cells up to 4 uM after 48 hrs in presence of ascorbic acid and beta-glycerophosphate by Western blot analysis | 2017 | Journal of natural products, 02-24, Volume: 80, Issue:2 | Anti-Osteoporotic Activity of Harpagoside by Upregulation of the BMP2 and Wnt Signaling Pathways in Osteoblasts and Suppression of Differentiation in Osteoclasts. |
| AID612352 | Effect on basal COX-2 mRNA expression in mouse RAW264.7 cells at 20 uM by RT-PCR | 2011 | Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16 | Effects of β-glucosidase hydrolyzed products of harpagide and harpagoside on cyclooxygenase-2 (COX-2) in vitro. |
| AID361435 | Neuroprotective activity against Sprague-Dawley rat cortical neurons assessed as glutamate-induced LDH release at 1 uM for 1 hr before glutamate challenge measured after 24 hrs by spectrophotometry | 2002 | Journal of natural products, Nov, Volume: 65, Issue:11 | Four new neuroprotective iridoid glycosides from Scrophularia buergeriana roots. |
| AID1483769 | Anti-osteoporotic activity in ovariectomized ICR mouse assessed as suppression of changes in trabecular separation in femur at 2 to 10 mg/kg, po after 12 weeks by microcomputed tomography | 2017 | Journal of natural products, 02-24, Volume: 80, Issue:2 | Anti-Osteoporotic Activity of Harpagoside by Upregulation of the BMP2 and Wnt Signaling Pathways in Osteoblasts and Suppression of Differentiation in Osteoclasts. |
| AID1483740 | Antiosteoporotic activity in mouse MC3T3-E1 cells assessed as increase in alkaline phosphatase activity after 4 days using pNPP as substrate in presence of ascorbic acid and beta-glycerophosphate by colorimetric assay | 2017 | Journal of natural products, 02-24, Volume: 80, Issue:2 | Anti-Osteoporotic Activity of Harpagoside by Upregulation of the BMP2 and Wnt Signaling Pathways in Osteoblasts and Suppression of Differentiation in Osteoclasts. |
| AID1243548 | Inhibition of RANKL-mediated ERK phosphorylation in mouse BMMC at 100 uM after 1 hr by Western blot analysis | 2015 | Journal of natural products, Sep-25, Volume: 78, Issue:9 | Harpagoside Inhibits RANKL-Induced Osteoclastogenesis via Syk-Btk-PLCγ2-Ca(2+) Signaling Pathway and Prevents Inflammation-Mediated Bone Loss. |
| AID1483743 | Upregulation of OPG protein expression in mouse MC3T3-E1 cells up to 4 uM after 48 hrs in presence of ascorbic acid and beta-glycerophosphate by Western blot analysis | 2017 | Journal of natural products, 02-24, Volume: 80, Issue:2 | Anti-Osteoporotic Activity of Harpagoside by Upregulation of the BMP2 and Wnt Signaling Pathways in Osteoblasts and Suppression of Differentiation in Osteoclasts. |
| AID1483758 | Activation of Wnt signaling pathway in mouse MC3T3-E1 cells assessed as upregulation of C-Myc protein expression after 48 hrs in presence of ascorbic acid and beta-glycerophosphate by Western blot analysis | 2017 | Journal of natural products, 02-24, Volume: 80, Issue:2 | Anti-Osteoporotic Activity of Harpagoside by Upregulation of the BMP2 and Wnt Signaling Pathways in Osteoblasts and Suppression of Differentiation in Osteoclasts. |
| AID1483777 | Effect on potassium level in serum of OVX-induced bone loss ICR mouse model at 5 mg/kg, po for 12 weeks by ELISA (Rvb = 8.2 +/- 0.4 mg/dl) | 2017 | Journal of natural products, 02-24, Volume: 80, Issue:2 | Anti-Osteoporotic Activity of Harpagoside by Upregulation of the BMP2 and Wnt Signaling Pathways in Osteoblasts and Suppression of Differentiation in Osteoclasts. |
| AID1243563 | Inhibition of LPS-induced bone loss in ICR mouse assessed as reduction of CTX-I in serum at 10 mg/kg, po after 10 days by ELISA | 2015 | Journal of natural products, Sep-25, Volume: 78, Issue:9 | Harpagoside Inhibits RANKL-Induced Osteoclastogenesis via Syk-Btk-PLCγ2-Ca(2+) Signaling Pathway and Prevents Inflammation-Mediated Bone Loss. |
| AID1483746 | Increase in ALP mRNA expression in 2 days differentiated mouse MC3T3-E1 cells up to 4 uM after 48 hrs in presence of ascorbic acid and beta-glycerophosphate by real-time PCR analysis | 2017 | Journal of natural products, 02-24, Volume: 80, Issue:2 | Anti-Osteoporotic Activity of Harpagoside by Upregulation of the BMP2 and Wnt Signaling Pathways in Osteoblasts and Suppression of Differentiation in Osteoclasts. |
| AID1243570 | Inhibition of ovariectomized-induced bone loss in C57BL/6 mouse assessed as restoration number of osteoclasts in femurs at 10 mg/kg, po administered every other day for 28 days | 2015 | Journal of natural products, Sep-25, Volume: 78, Issue:9 | Harpagoside Inhibits RANKL-Induced Osteoclastogenesis via Syk-Btk-PLCγ2-Ca(2+) Signaling Pathway and Prevents Inflammation-Mediated Bone Loss. |
| AID1243550 | Inhibition of RANKL-mediated Syk phosphorylation in mouse BMMC at 100 uM after 1 hr by Western blot analysis | 2015 | Journal of natural products, Sep-25, Volume: 78, Issue:9 | Harpagoside Inhibits RANKL-Induced Osteoclastogenesis via Syk-Btk-PLCγ2-Ca(2+) Signaling Pathway and Prevents Inflammation-Mediated Bone Loss. |
| AID1243560 | Inhibition of LPS-induced bone loss in ICR mouse assessed as restoration of osteoclast formation in femurs at 10 mg/kg, po after 10 days by hematoxylin and eosin staining | 2015 | Journal of natural products, Sep-25, Volume: 78, Issue:9 | Harpagoside Inhibits RANKL-Induced Osteoclastogenesis via Syk-Btk-PLCγ2-Ca(2+) Signaling Pathway and Prevents Inflammation-Mediated Bone Loss. |
| AID1483756 | Upregulation of beta-catenin protein expression in mouse MC3T3-E1 cells after 48 hrs in presence of ascorbic acid and beta-glycerophosphate by Western blot analysis | 2017 | Journal of natural products, 02-24, Volume: 80, Issue:2 | Anti-Osteoporotic Activity of Harpagoside by Upregulation of the BMP2 and Wnt Signaling Pathways in Osteoblasts and Suppression of Differentiation in Osteoclasts. |
| AID494084 | Antiinflammatory activity in HUVEC assessed as inhibition of TNF-alpha-induced E-selection expression after 2 hrs by ELISA | 2010 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 20, Issue:16 | Morroniside cinnamic acid conjugate as an anti-inflammatory agent. |
| AID612348 | Inhibition of human recombinant COX2 at 2.5 to 100 uM incubated for 10 mins by enzyme immunoassay | 2011 | Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16 | Effects of β-glucosidase hydrolyzed products of harpagide and harpagoside on cyclooxygenase-2 (COX-2) in vitro. |
| AID1483793 | Effect on C-terminal telopeptide level in serum of OVX-induced bone loss ICR mouse model at 5 mg/kg, po for 12 weeks by ELISA (Rvb = 95.7 +/- 3.8 ng/ml) | 2017 | Journal of natural products, 02-24, Volume: 80, Issue:2 | Anti-Osteoporotic Activity of Harpagoside by Upregulation of the BMP2 and Wnt Signaling Pathways in Osteoblasts and Suppression of Differentiation in Osteoclasts. |
| AID612346 | Cytotoxicity against mouse RAW264.7 cells at 2.5 to 100 uM after 18 hrs by MTT assay | 2011 | Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16 | Effects of β-glucosidase hydrolyzed products of harpagide and harpagoside on cyclooxygenase-2 (COX-2) in vitro. |
| AID1483785 | Effect on TRAP activity in serum of OVX-induced bone loss ICR mouse model at 5 mg/kg, po for 12 weeks (Rvb = 19.8 +/- 1.0 U/L) | 2017 | Journal of natural products, 02-24, Volume: 80, Issue:2 | Anti-Osteoporotic Activity of Harpagoside by Upregulation of the BMP2 and Wnt Signaling Pathways in Osteoblasts and Suppression of Differentiation in Osteoclasts. |
| AID1243538 | Inhibition of RANKL-mediated osteoclastogenesis in mouse BMMC assessed as reduction of c-Fos protein expression at 100 uM after 12 to 48 hrs by Western blot analysis | 2015 | Journal of natural products, Sep-25, Volume: 78, Issue:9 | Harpagoside Inhibits RANKL-Induced Osteoclastogenesis via Syk-Btk-PLCγ2-Ca(2+) Signaling Pathway and Prevents Inflammation-Mediated Bone Loss. |
| AID385232 | Inhibition of COX2 synthesis in pig skin | 2008 | Journal of natural products, May, Volume: 71, Issue:5 | Effect of the major glycosides of Harpagophytum procumbens (Devil's Claw) on epidermal cyclooxygenase-2 (COX-2) in vitro. |
| AID612354 | Inhibition of LPS-induced COX-2 mRNA expression in mouse RAW264.7 cells at 100 uM pre-incubated for 3 hrs before LPS challenge measured 24 hrs post LPS challenge by RT-PCR | 2011 | Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16 | Effects of β-glucosidase hydrolyzed products of harpagide and harpagoside on cyclooxygenase-2 (COX-2) in vitro. |
| AID612356 | Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells at 2.5 to 100 uM pre-incubated for 20 mins before LPS challenge measured 18 hrs post LPS challenge by Griess method | 2011 | Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16 | Effects of β-glucosidase hydrolyzed products of harpagide and harpagoside on cyclooxygenase-2 (COX-2) in vitro. |
| AID1243536 | Inhibition of RANKL-mediated osteoclast differentiation in mouse BMMC assessed as disruption of F-actin ring formation after 3 days using phalloidin and DAPI staining | 2015 | Journal of natural products, Sep-25, Volume: 78, Issue:9 | Harpagoside Inhibits RANKL-Induced Osteoclastogenesis via Syk-Btk-PLCγ2-Ca(2+) Signaling Pathway and Prevents Inflammation-Mediated Bone Loss. |
| AID1243535 | Cytotoxicity against mouse BMMC assessed as cell viability after 3 days by XTT assay | 2015 | Journal of natural products, Sep-25, Volume: 78, Issue:9 | Harpagoside Inhibits RANKL-Induced Osteoclastogenesis via Syk-Btk-PLCγ2-Ca(2+) Signaling Pathway and Prevents Inflammation-Mediated Bone Loss. |
| AID467894 | Antiviral activity against HCV expressing E1E2 glycoprotein with Vpr-deficient HIV vector assessed as inhibition of viral entry in human Huh7 cells at 20 ug/ml measured after 72 hrs by luciferase reporter gene assay | 2009 | Journal of natural products, Dec, Volume: 72, Issue:12 | Lamiridosins, hepatitis C virus entry inhibitors from Lamium album. |
| AID1243551 | Inhibition of RANKL-mediated Btk phosphorylation in mouse BMMC at 100 uM after 1 hr by Western blot analysis | 2015 | Journal of natural products, Sep-25, Volume: 78, Issue:9 | Harpagoside Inhibits RANKL-Induced Osteoclastogenesis via Syk-Btk-PLCγ2-Ca(2+) Signaling Pathway and Prevents Inflammation-Mediated Bone Loss. |
| AID1243564 | Inhibition of ovariectomized-induced bone loss in C57BL/6 mouse assessed as reduction of loss of bone mineral density at 10 mg/kg, po administered every other day for 28 days by micro-CT analysis | 2015 | Journal of natural products, Sep-25, Volume: 78, Issue:9 | Harpagoside Inhibits RANKL-Induced Osteoclastogenesis via Syk-Btk-PLCγ2-Ca(2+) Signaling Pathway and Prevents Inflammation-Mediated Bone Loss. |
| AID612353 | Effect on basal COX-2 mRNA expression in mouse RAW264.7 cells at 100 uM by RT-PCR | 2011 | Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16 | Effects of β-glucosidase hydrolyzed products of harpagide and harpagoside on cyclooxygenase-2 (COX-2) in vitro. |
| AID1483744 | Decrease in RANKL mRNA expression in mouse MC3T3-E1 cells at up to 4 uM after 48 hrs in presence of ascorbic acid and beta-glycerophosphate by real-time PCR analysis | 2017 | Journal of natural products, 02-24, Volume: 80, Issue:2 | Anti-Osteoporotic Activity of Harpagoside by Upregulation of the BMP2 and Wnt Signaling Pathways in Osteoblasts and Suppression of Differentiation in Osteoclasts. |
| AID467895 | Antiviral activity against HCV expressing E1E2 glycoprotein with Vpr-deficient HIV vector assessed as inhibition of viral entry in human Huh7 cells at 20 ug/ml after 72 hrs by luciferase reporter gene assay in presence of beta-glucosidase enzyme for 0.5 h | 2009 | Journal of natural products, Dec, Volume: 72, Issue:12 | Lamiridosins, hepatitis C virus entry inhibitors from Lamium album. |
| AID1483798 | Increase in OPG to RANKL mRNA expression ratio in mouse MC3T3-E1 cells up to 4 uM after 48 hrs in presence of ascorbic acid and beta-glycerophosphate by real-time PCR analysis | 2017 | Journal of natural products, 02-24, Volume: 80, Issue:2 | Anti-Osteoporotic Activity of Harpagoside by Upregulation of the BMP2 and Wnt Signaling Pathways in Osteoblasts and Suppression of Differentiation in Osteoclasts. |
| AID1483788 | Effect on osteocalcin level in serum of OVX-induced bone loss ICR mouse model at 2 mg/kg, po for 12 weeks by ELISA (Rvb = 176.9 +/- 4.7 ng/ml) | 2017 | Journal of natural products, 02-24, Volume: 80, Issue:2 | Anti-Osteoporotic Activity of Harpagoside by Upregulation of the BMP2 and Wnt Signaling Pathways in Osteoblasts and Suppression of Differentiation in Osteoclasts. |
| AID1243539 | Inhibition of RANKL-mediated osteoclastogenesis in mouse BMMC assessed as reduction of NFATc1 protein expression at 100 uM after 12 to 48 hrs by Western blot analysis | 2015 | Journal of natural products, Sep-25, Volume: 78, Issue:9 | Harpagoside Inhibits RANKL-Induced Osteoclastogenesis via Syk-Btk-PLCγ2-Ca(2+) Signaling Pathway and Prevents Inflammation-Mediated Bone Loss. |
| AID1243540 | Inhibition of RANKL-mediated osteoclastogenesis in mouse BMMC assessed as reduction of c-Fos mRNA expression at 100 uM after 12 to 48 hrs by RT-PCR analysis | 2015 | Journal of natural products, Sep-25, Volume: 78, Issue:9 | Harpagoside Inhibits RANKL-Induced Osteoclastogenesis via Syk-Btk-PLCγ2-Ca(2+) Signaling Pathway and Prevents Inflammation-Mediated Bone Loss. |
| AID385235 | Suppression of COX2 expression in pig skin by immunostaining after 6 hrs | 2008 | Journal of natural products, May, Volume: 71, Issue:5 | Effect of the major glycosides of Harpagophytum procumbens (Devil's Claw) on epidermal cyclooxygenase-2 (COX-2) in vitro. |
| AID1243546 | Inhibition of RANKL-mediated osteoclastogenesis in mouse BMMC assessed as reduction of CTR mRNA expression at 100 uM after 12 to 48 hrs by RT-PCR analysis | 2015 | Journal of natural products, Sep-25, Volume: 78, Issue:9 | Harpagoside Inhibits RANKL-Induced Osteoclastogenesis via Syk-Btk-PLCγ2-Ca(2+) Signaling Pathway and Prevents Inflammation-Mediated Bone Loss. |
| AID1243547 | Inhibition of RANKL-mediated osteoclastogenesis in mouse BMMC assessed as reduction of cathepsin K mRNA expression at 100 uM after 12 to 48 hrs by RT-PCR analysis | 2015 | Journal of natural products, Sep-25, Volume: 78, Issue:9 | Harpagoside Inhibits RANKL-Induced Osteoclastogenesis via Syk-Btk-PLCγ2-Ca(2+) Signaling Pathway and Prevents Inflammation-Mediated Bone Loss. |
| AID612357 | Inhibition of LPS-induced TNFalpha production in mouse RAW264.7 cells at 2.5 to 100 uM pre-incubated for 30 mins before LPS challenge measured 6 hrs post LPS challenge by ELISA | 2011 | Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16 | Effects of β-glucosidase hydrolyzed products of harpagide and harpagoside on cyclooxygenase-2 (COX-2) in vitro. |
| AID1483760 | Inhibition of RANKL/M-CSF-induced osteoclast differentiation in mouse bone marrow-derived osteoclasts assessed as reduction in formation of TRAP-positive cells after 5 days | 2017 | Journal of natural products, 02-24, Volume: 80, Issue:2 | Anti-Osteoporotic Activity of Harpagoside by Upregulation of the BMP2 and Wnt Signaling Pathways in Osteoblasts and Suppression of Differentiation in Osteoclasts. |
| AID1243543 | Inhibition of RANKL-mediated osteoclastogenesis in mouse BMMC assessed as reduction of OSCAR mRNA expression at 100 uM after 12 to 48 hrs by RT-PCR analysis | 2015 | Journal of natural products, Sep-25, Volume: 78, Issue:9 | Harpagoside Inhibits RANKL-Induced Osteoclastogenesis via Syk-Btk-PLCγ2-Ca(2+) Signaling Pathway and Prevents Inflammation-Mediated Bone Loss. |
| AID1483750 | Activation of Wnt signaling pathway in mouse MC3T3-E1 cells assessed as increase in BMP2 mRNA expression after 48 hrs in presence of ascorbic acid and beta-glycerophosphate by real-time PCR analysis | 2017 | Journal of natural products, 02-24, Volume: 80, Issue:2 | Anti-Osteoporotic Activity of Harpagoside by Upregulation of the BMP2 and Wnt Signaling Pathways in Osteoblasts and Suppression of Differentiation in Osteoclasts. |
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (3.33) | 18.7374 |
| 1990's | 5 (5.56) | 18.2507 |
| 2000's | 30 (33.33) | 29.6817 |
| 2010's | 44 (48.89) | 24.3611 |
| 2020's | 8 (8.89) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (28.55) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 4 (4.26%) | 5.53% |
| Reviews | 2 (2.13%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 88 (93.62%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||